Paclitaxel therapy for angiosarcoma

Paclitaxel therapy for angiosarcoma - Paclitaxel therapy for angiosarcoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003243

Enrollment

Registered

2010-02-24

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angiosarcoma

Interventions

tri-weekly paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Angiosarcoma patients who dincontinued DTX because of drug-induced interstitial pneumonia

Exclusion criteria

Exclusion criteria: 1 Allergy to Paclitaxel or components 2 Infectious disease 3 Severe liver, kidney, heart, lung, gastro-intestinal,bone marrow disease 4 Pregnant or feeding baby 5 Considered as Inappropriate for the study by doctors

Design outcomes

Primary

Measure	Time frame
physical examination, chest X-ray, CT scan	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026